RRAS is a small GTPase that functions as a molecular switch regulating multiple cellular processes through activation of MAPK and PI3K-mTOR signaling pathways 1. The protein controls cell adhesion, migration, and actin cytoskeleton organization 2, with documented roles in integrin beta-1 modulation [UniProt]. In normal physiology, RRAS expression is transcriptionally regulated by FOXF1 in lung endothelial cells, where it suppresses fibroblast activation and pulmonary inflammation—processes dysregulated in idiopathic pulmonary fibrosis 3. Clinically, RRAS mutations drive disease through two distinct mechanisms: (1) Germline mutations cause RASopathies, particularly Noonan syndrome, as rare but pathogenic variants affecting the RAS/MAPK pathway 4; (2) Somatic mutations, specifically RRAS Q87L (homologous to KRAS Q61), represent recurrent oncogenic drivers in ~0.45% of non-small cell lung cancers and oral squamous cell carcinomas, activating canonical growth signaling and conferring sensitivity to pan-RAS inhibitor RMC-6236 15. In acute megakaryoblastic leukemia, elevated RRAS promotes immune escape via enhanced ERK signaling and reduced CD8+ T cell anti-tumor immunity 2. Therapeutically, RRAS shows promise as a therapeutic target for glucose regulation in diabetes when enhanced PI3Kα binding is pharmacologically modulated 6, while emerging as a prognostic marker for treatment response and recurrence risk in multiple cancer types 7.